Cancer drug shortages aren’t new. Nor are the proposed solutions. But the critical nature of the public health emergency may serve as a call to federal government action.
NATIONAL ZIRABEV SHORTAGE !
Pfizer, the manufacturer of Zirabev a bevacizumab biosimilar, has announced widespread manufacturing delays. At this time there is insufficient supply for ordering. The current supply is expected to be depleted in September. If your treatment regimen includes Zirabev, your provider will be reviewing alternative biosimilars or modifications to your treatment plan as may be necessary and will discuss options with you at your visit.